Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Compounding Oversight May Hinge On How FDA Treats Office Stock

Executive Summary

Pew asks FDA to look at large-scale compounders of office stocks and help encourage them to register, but IACP argues regulation of the office stock should remain with the states.

You may also be interested in...



FDA's Budget Flat In House Bill, But Path For 'Cures' Funding Cleared

US agency's budget authority would remain at current level under FY 2018 appropriations bill reported out by a House subcommittee; measure includes language enabling FDA's Oncology Center of Excellence to receive 21st Century Cures funding transferred from National institutes of Health.

FDA Compounder Inspections May Help Set New Enforcement Standard

Agency releases 483 forms from a post-crises inspection push; the effort may help FDA illustrate its inspection capabilities to Congress and states and indicate the agency’s oversight plans under the new authority it has proposed.

BsUFA III Talks Could Move Cloud-Platform Goals Forward

US FDA wants to use biosimilars for a demonstration of cloud-based technology, an idea mentioned to increase the use of real-time review and enhance data analysis.

Topics

UsernamePublicRestriction

Register

PS055920

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel